Addressing Challenges in Antibody-Drug Conjugate Development

Introduction:

Antibody-drug conjugates (ADCs) combine monoclonal antibodies with potent cytotoxic drugs to enable precise cancer targeting. However, challenges remain in conjugation efficiency, controlled drug release, and safety.

What You Can Expect:

▶ Optimize antibody selection for improved targeting and internalization

▶ Enhance conjugation efficiency and ensure consistent DAR

▶ Design stable linkers for controlled payload release

▶ Evaluate payload delivery and overall therapeutic efficacy